Stock Movers: Medtronic, Merck, Nvidia (Podcast)

Medtronic rallied 4.6%, the top S&P gainer, after raising the bottom end of its adjusted profit guidance and lifting its organic revenue outlook following stronger-than-expected Q2 results; Merck climbed to its highest level since March after a mid‑stage trial of its rare‑hypertension drug Winrevair met its primary endpoint, suggesting a materially larger potential market. Technology names cooled ahead of Nvidia’s earnings with NVDA down 2.8%; separately Nvidia and Microsoft committed up to a combined $15 billion to Anthropic, a strategic capital allocation that further concentrates backing behind an OpenAI rival and could influence AI investment flows.

Analysis

Medtronic shares rallied 4.6%, the largest S&P gainer, after the medical‑device maker raised the bottom end of its adjusted profit forecast and boosted its organic revenue outlook following stronger‑than‑expected second‑quarter results. The guidance tweak suggests management sees more durable margin or revenue traction this year, which may prompt analysts to lift FY estimates if supported by detailed segment metrics and margin drivers.

Merck shares climbed to the highest level since March after a mid‑stage trial for Winrevair, a treatment for a rare form of high blood pressure, met its primary endpoint, indicating potential to expand addressable market and commercial upside if positive data hold through late‑stage development and regulators. The result materially de‑risks that program but remains contingent on confirmatory trials and timelines to approval and launch, so near‑term revenue impact is prospective rather than immediate.

Nvidia closed down 2.8% amid persistent tech weakness ahead of its earnings, even as Nvidia and Microsoft committed up to a combined $15 billion to Anthropic, deepening ties to an OpenAI rival and concentrating AI investment flows. The capital allocation underscores strategic jockeying in AI infrastructure and partnerships, but the stock reaction highlights event‑risk around NVDA’s upcoming report and ongoing investor sensitivity to near‑term earnings and guidance.

Key Decisions for Investors

• Consider adding or initiating a selective long on Medtronic on the guidance upgrade, but verify segment‑level drivers and margin sustainability before increasing position
• Monitor Merck trial readouts and regulatory pathway for Winrevair; position size toward Merck could be increased on positive confirmatory data or clearer commercialization assumptions
• Exercise caution into Nvidia earnings despite the Anthropic investment; trim or hedge tech exposure ahead of the report if portfolio is earnings‑sensitive
• Watch broader AI capital flows and competitive implications of the $15 billion Anthropic commitment as it may shift partnership and platform dynamics in the sector
• Use options or short‑dated hedges to protect portfolios from event‑driven volatility in major tech names while awaiting earnings and clinical confirmation